27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
The primary analysis demonstrated significant improvements in multiple episodic memory measures across both intervention groups, with no significant differences observed between groups. 5 key findings →
Design: post-hoc analysis Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
BackgroundDementia impacts individuals, families, and society, necessitating effective prevention strategies. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Cognitive decline occurs in all persons during the aging process. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
This narrative review examines literature pertaining to possible physiological explanations for observed cognitive benefits stemming from improvements to cardiovascular fitness following chronic aerobic exercise. 5 key findings →
Design: narrative review Evidence: low
Full summary, score breakdown and related studies → Original source
Psychosocial stress and physical, cognitive, and social activity predict the risk of cognitive decline and dementia. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Diet is the single most significant risk factor for disability and premature death. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Improved life expectancy worldwide has resulted in a significant increase in age-related diseases. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
All people want to age "successfully," maintaining functional capacity and quality of life as they reach advanced age. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
With the world's population aging at a rapid rate, the prevalence of Alzheimer's disease (AD) has significantly increased. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Cognitive dysfunction is common in Parkinson's disease (PD) and predicts poor clinical outcomes. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Recent findings Results suggest that higher adherence to a healthy dietary pattern is associated with preservation of brain structure and function as well as slower cognitive decline, with the MIND diet substantially slowing cognitive decline, over and above the MeDi and DASH diets. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Good cognitive abilities (CA) enable autonomy, improve social inclusion and act preventively. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Physical and cognitive frailty are interrelated and synergistic syndromes more frequently seen in old age, which represent intermediate stages between aging successfully and disability. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
This review summarises the most recent evidence regarding the effects of diet in preventing and reducing age-related cognitive decline and neurodegenerative diseases. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Previous research has demonstrated beneficial impact of spermidine intake on memory functions in both animal models and humans, suggesting that spermidine may be a preventive approach to delay age-related cognitive decline and possibly even Alzheimer's disease (AD). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The decline in cognitive function is generally the result of the complex interaction of several factors. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer's disease (AD) is a neurodegenerative disorder without a known cure or effective treatment. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Aging-related cognitive decline represents a critical risk factor for the development of dementia and is associated with global neurophysiological changes. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
There was a lack of definitive evidence of effectiveness for most psychosocial interventions. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Development of measures to preserve cognitive function or even reverse cognitive decline in the ever-growing elderly population is the focus of many research and commercial efforts. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Since its discovery some hundred years ago, Alzheimer's disease (AD), a neurodegenerative disease and an eminent cause of most dementia, continues to pose problems for affected families and society, especially in developed countries. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Exercise programs involving aerobic and resistance training (i.e., multiple-modality) have shown promise in improving cognition and executive control in older adults at risk, or experiencing, cognitive decline. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
In this review we summarize the research pertaining to the role of exercise in preventing cognitive decline in patients with end-stage kidney disease (ESKD). 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer's disease (AD) is characterized by the presence of amyloid-β (Aβ), oxidative damage and neuronal degeneration, which, together with other pathological events, promote progressive memory loss and cognitive decline. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Recent years have witnessed a revolution in our understanding of microglia biology, including their major role in the etiology and pathogenesis of neurodegenerative diseases. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →